Clinical trials: Cardiovascular Condition
Cardiac Arrhythmia
Mobile Cardiac Telemetry and Advanced Multi-Parameter Monitoring in PatientS Wearing a Novel Device With Biometric Based Medications Changes
To determine the associations among biometric data and previously reported medication changes in the original MAPS study
- Trial name
- MAPS II (NCT05505136)
- Testing
- Arrhythmia Management System (AMS)
- Where
- 8 sites in United States
- Volunteers
- 62 people
- Sponsor
- Zoll Medical Corporation
Paroxysmal Atrial Fibrillation
Study of HD Mesh Ablation System for Treatment of Paroxysmal Atrial Fibrillation
This is a randomized controlled study of the Bard High Density Mesh Ablation System for treatment of paroxysmal atrial fibrillation.
- Trial name
- MAGELLAN (NCT00741611)
- Testing
- HD Mesh Ablation System, Anti-arrhythmic drugs
- Where
- 13 sites in United States
- Volunteers
- 44 people
- Sponsor
- C. R. Bard
MELAS Syndrome, Mitochondrial Respiratory Chain Deficiencies
Safety, Tolerability and Pharmacokinetic Study of KL1333 in Healthy Male Volunteers
The purpose of this First In Human study is to investigate the safety and tolerability of KL1333 after a single oral dose and to investigate the pharmacokinetic characteristics of KL1333 after a single oral dose.
- Trial name
- NCT03056209
- Testing
- KL1333 25 mg, KL1333 50 mg, KL1333 100 mg
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Yungjin Pharm. Co., Ltd.
Arrhythmias, Cardiac
An Observational Post-marketing Study Using Commercially Approved Biosense Webster (BWI) Medical Devices for the Treatment of Participants With Cardiac Arrhythmias
The purpose of this study is to prospectively collect clinical data evaluating the ongoing safety and performance during routine-use standard cardiac arrhythmia mapping and/or ablation procedures while using commercial Biosense…
- Trial name
- SECURE (NCT04750798)
- Testing
- BWI Medical Device, Varipulse Catheter, Dual Energy THERMOCOOL SMARTTOUCH SF Catheter
- Where
- 47 sites in Austria, Belgium and 13 more
- Volunteers
- 8,000 people
- Sponsor
- Biosense Webster, Inc.
Overweight, Obesity
A Master Protocol for Semaglutide Effects on Cardiovascular and Obesity-related Outcomes in People With Overweight or Obesity in the Real World
This study aims to evaluate the association of once-weekly semaglutide with the risk of cardiovascular (CV) and other obesity-related clinical outcomes in three study populations (Heart failure (HF), clinical Atherosclerotic…
- Conditions
- Overweight, Obesity, Heart Failure (HF), Atherosclerotic Cardiovascular Disease (ASCVD)
- Trial name
- NCT07141914
- Testing
- No treatment given
- Where
- United States
- Volunteers
- 285,327 people
- Sponsor
- Novo Nordisk A/S
Coronary Artery Disease
Prevention of Autogenous Vein Graft Failure in Coronary Artery Bypass Procedures
The purpose of this study is to determine the efficacy of graft pretreatment with CGT003 (E2F Duplex Decoy), as compared to placebo, on the incidence of patients experiencing vein graft failure after coronary artery bypass…
- Trial name
- NCT00042081
- Testing
- CGT003 (E2F Duplex Decoy)
- Where
- 154 sites in United States
- Volunteers
- 3,000 people
- Sponsor
- Anesiva, Inc.
Coronary Artery Disease
Evaluation of Coronary Luminal Diameter Enlargement With Emerge™ 1.20 mm PTCA Dilatation Catheter
To evaluate the acute safety and device procedural success of the Emerge 1.20 mm PTCA dilatation catheter when used as a pre-dilatation device in the stenotic portion of coronary arteries or bypass grafts.
- Trial name
- NCT01635881
- Testing
- Emerge™ 1.20 mm PTCA Dilatation Catheter
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Boston Scientific Corporation
Heart Failure
Monitor Patients With Acute Heart Failure
This is a prospective, multi-center, non-randomized study to evaluate performance of an external monitor for heart failure patients
- Trial name
- ACUTE (NCT00919828)
- Testing
- Avivo System
- Volunteers
- 60 people
- Sponsor
- Corventis, Inc.
Relapsed/Refractory Multiple Myeloma(MM)
LCAR-F33S in Treatment of Relapsed/Refractory Multiple Myeloma
A prospective, single-arm, open-label dose-exploration and expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor efficacy characteristics of LCAR-F33S in patients with relapsed/refractory multiple…
- Trial name
- NCT07100067
- Testing
- LCAR- F33S cells intravenous infusion
- Where
- 4 sites in China
- Volunteers
- 35 people
- Sponsor
- Nanjing Legend Biotech Co.
Prevention of Arterial and Venous Thrombosis
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Single-dose Injection of SHR-2004 in Healthy Subjects
The primary objective of this study is to assess the safety and tolerability of SHR-2004 injection in healthy subjects. In addition, this study will provide information on pharmacokinetics and pharmacodynamics of SHR-2004…
- Trial name
- NCT05369767
- Testing
- SAD, SHR-2004
- Where
- China
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Beijing Suncadia Pharmaceuticals Co., Ltd
Cardiovascular Events, MACE
Tezspire Cardiac Events PASS
The aim of this study is to evaluate the risk of serious adverse cardiovascular events in adolescent and adult patients with severe asthma taking tezepelumab compared to a population receiving standard of care treatment for…
- Trial name
- TRESPASS (NCT06951867)
- Testing
- Tezepelumab
- Where
- 4 sites in United States, Denmark and 2 more
- Volunteers
- 16,640 people
- Sponsor
- AstraZeneca
Venous Thromboembolism
Edoxaban Treatment in Routine Clinical Practice in Patients With Venous Thromboembolism in Europe
According to current guidelines, duration of anticoagulant treatment after a venous thromboembolic event varies from 3 months to indefinite treatment depending on the estimated risks of venous thromboembolism (VTE) recurrence and…
- Trial name
- ETNA-VTE (NCT02943993)
- Testing
- Edoxaban
- Where
- Germany
- Volunteers
- 2,809 people
- Sponsor
- Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Coronary Artery Disease
Equity in Modifying Plaque Of WomEn With UndeRtreated Calcified Coronary Artery Disease
Post-market, prospective, multi-center, single-arm observational study to generate real-world clinical evidence associated with coronary IVL in a population of female subjects with calcified coronary artery disease.
- Trial name
- EMPOWER CAD (NCT05755711)
- Testing
- Shockwave Medical Coronary IVL System
- Where
- 49 sites in United States, France and 3 more
- Volunteers
- 399 people
- Sponsor
- Shockwave Medical, Inc.
Healthy
Validation of the Masimo Irregular Heartbeat Detection Algorithm in Participants Without Cardiovascular Disease
Specificity measure of performance of the Irregular Heartbeat Detection algorithm (evaluated for the finger and wrist form factors) against the Masimo Radius VSM® reference ECG.
- Trial name
- NCT07223164
- Testing
- Masimo SET® and Masimo W1®
- Where
- United States
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Masimo Corporation
Hypertension
Evaluate the Pharmacokinetic Interaction and the Safety of AD-2321 and AD-2322
To evaluate the pharmacokinetic interactions of AD-2321, AD-2322 in healthy adult volunteers.
- Trial name
- NCT07312799
- Testing
- Treatment A(AD-2321), Treatment B(AD-2322), Treatment C(AD-2321+AD-2322)
- Where
- South Korea
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Hypertension, Metabolic Syndrome X
Clinical EvaluatioN of TElmisartan-based Antihypertensive Regimen
To determine the efficacy and safety of telmisartan-based treatment among patients with metabolic syndrome in actual setting in Philippines.
- Trial name
- NCT00613314
- Where
- 122 sites in Philippines
- Volunteers
- 15,268 people
- Sponsor
- Boehringer Ingelheim
Systemic Sclerosis
Open-Label Study of Oral Treprostinil in Digital Ulcers
This open label extension trial will allow ongoing treatment of subjects who participated in the randomized controlled trials, and will provide long term information about the safety of treprostinil diethanolamine SR in subjects…
- Trial name
- DISTOL-EXT (NCT00848107)
- Testing
- treprostinil diethanolamine
- Where
- 26 sites in United States, Canada and 1 more
- Volunteers
- 115 people
- Sponsor
- United Therapeutics
Essential Hypertension
Efficacy and Safety of Lercanidipine and Enalapril in Patients With Essential Hypertension
The purpose of this study is to evaluate the efficacy and safety of various dosage combinations of lercanidipine (10 and 20 mg)and enalapril (10 and 20 mg) in comparison with their respective components and with placebo.
- Trial name
- FELT (NCT01093807)
- Testing
- Lercanidipine, Enalapril, Lercanidipine + Enalapril
- Where
- France
- Volunteers
- 1,039 people
- Sponsor
- RECORDATI GROUP
Multiple Myeloma
A Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple Myeloma
This is a Phase 3, randomized, open-label, multicenter study comparing two treatment regimens for subjects with multiple myeloma who have received all available approved treatment options and may therefore be considered…
- Trial name
- FOCUS (NCT01302392)
- Testing
- Carfilzomib, Best Supportive Care
- Where
- 68 sites in Australia, Austria and 17 more
- Volunteers
- 315 people
- Sponsor
- Amgen
Aortic Valve Stenosis
HLT Meridian Valve CE Mark Trial
To evaluate the safety and performance of the HLT System in patients with symptomatic heart disease due to severe aortic stenosis who are judged by the Heart Team to be at Intermediate or High Risk for aortic valve replacement…
- Trial name
- RADIANT CE (NCT03805711)
- Testing
- HLT® Transcatheter System
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- HLT Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.